KDR and hepatocellular carcinoma: On this basis, this study clearly indicates that 131I-labeled chimeric anti-VEGFR2 Fab could be used as a therapeutic drug for RAIT through targeting VEGFR2 antigen with anti-apoptotic and necrosis effects in HCC xenograft model in mice.